Gsk (GSK) Gross Margin (2009 - 2026)

Gsk (GSK) has 18 years of Gross Margin data on file, last reported at 74.18% in Q3 2026.

• For the quarter ending Q3 2026, Gross Margin changed N/A year-over-year to 74.18%; the trailing twelve-month figure through Sep 2026 stood at 54.46% (changed N/A YoY), and the FY2025 full-year result was 72.4%, up 123.0% from the prior year.
• Gross Margin was 74.18% for Q3 2026 at Gsk, up from 73.05% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 75.42% in Q1 2026 to a low of 34.9% in Q4 2025.
• A 5-year average of 69.62% and a median of 72.89% in 2025 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin jumped 984 bps in 2023 and tumbled 3826 bps in 2025, its largest moves.
• Gsk's Gross Margin stood at 65.34% in 2022, then climbed by 11 bps to 72.57% in 2023, then advanced by 1 bps to 73.16% in 2024, then plunged by 52 bps to 34.9% in 2025, then surged by 113 bps to 74.18% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 74.18% in Q3 2026, 73.05% in Q2 2026, and 75.42% in Q1 2026.